You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中銀國際微調康方生物(09926.HK)目標價至59元 評級「買入」
阿思達克 08-31 15:22
中銀國際發表評級報告指,康方生物(09926.HK)上半年實現收入及利潤分別為36.8億元人民幣及24.9億元人民幣,符合預期;AK104上半年銷售額為6.06億元人民幣,在上市後12個月內銷售額總計11.5億元人民幣,剔除許可收入後,得益於營運效率提高,上半年淨虧損由6.91億元人民幣收窄至2.56億元人民幣。 該行表示,考慮到內地醫藥反腐活動持續的不確定性,小幅削減今年AK104銷量預測,同時基於上半年銷量低於預期,亦削減AK105銷量預測。該行微調其目標價至59元,重申其評級「買入」。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account